Moreover, whether age remains an independent predictive prognostic factor, after adjustment of breast cancer subtype (ER, PR, and HER2 status), as well as, other known prognostic factors (TNM classification, adjuvant systemic therapy, etc.)has yet to be determined, given YA patients are at risk of developing more aggressive and more advanced breast cancers. This evidence concerns the gene ERBB2 and breast cancer.